PRNewsWire
21 Jun 2026, 11:58 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of channel stuffing to artificially inflate revenue. — Allegations of revenue manipulation (channel stuffing) strike at the core of financial integrity and typically lead to significant stock price volatility and loss of investor trust.
-0.80The lawsuit claims ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and hidden related-party deals suggest systemic governance failures and increase the risk of future financial restatements.
-0.60The Rosen Law Firm has set a deadline of August 10, 2026, for investors to move to serve as lead plaintiff in the case. — While a procedural step, the pursuit of a lead plaintiff formalizes the litigation process and keeps the negative claims in the public eye.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is the subject of a securities lawsuit filed by The Rosen Law Firm.
The company is facing a securities fraud class action lawsuit alleging channel stuffing and lack of internal controls.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
21h ago
